Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification. Significance: Amplification of the MET proto-oncogene is responsible for de novo and acquired resistance to anti-EGFR therapy in a subset of colorectal cancers. As multiple anti-MET therapeutic strategies are available, these findings offer immediate novel opportunities to design clinical studies. Cancer Discov; 3(6); 658–73. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 591
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A clinical study has demonstrated that MET amplification is associated with acquired resistance to cetuximab or panitumumab in patients with KRAS-WT mCRC [184].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [184]
The cited source says what the claim attributes to it.
In the citing paper
“HGF-induced MET activation as a mechanism of attenuated sensitivity to cetuximab in CRC has been reported by preclinical studies using either CRC cell lines [103, 104] or, more recently, CRC spheroids enriched in cancer stem cells [105].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [104]
In the citing paper
“Multi-arm preclinical trials in MET-positive CRC cell lines and patient-derived xenografts revealed that long-lasting abolition of tumor growth could be achieved through MET inhibition, with or without concurrent interception of EGFR [104, 107].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [104]
In the citing paper
“In these studies, only the simultaneous blockade of both MET and EGFR effectively impaired tumor growth in vivo.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [104]
In the citing paper
“However, this frequency increased to 12.5 % in a subpopulation of cetuximab-resistant xenopatients bearing wild-type forms of KRAS, NRAS, BRAF, PIK3CA, and HER2.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [104]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 3×
“Similar to what happens with other targeted agents, mCRC patients whose tumors respond to EGFR targeted antibodies develop acquired resistance within 3–12 months (5, 6).”
InfluentialSelf-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“It has been clearly established that KRAS mutational status is the key predictor of tumor suitability for anti-EGFR therapy (7, 8).”
Self-citationMichalopoulos, G. K., & DeFrances, M. C. (1997) · Science · doi:10.1126/science.276.5309.60 · Cited by 2,828
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Research works printed but not linked: 1
- Whitehead, 1985, A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer, J Natl Cancer Inst, 74, 759
Cited by
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Self-citationPatient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Self-citationClonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Self-citationConsensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Circulating Tumor DNA as a Liquid Biopsy for Cancer
Heitzer, E., Ulz, P., & Geigl, J. B. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.222679 · Cited by 767
Metadata
- Authors
- Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., Perera, T., Veronese, S., Corti, G., Amatu, A., Gambacorta, M., Diaz, L. A., Sausen, M., Velculescu, V. E., Comoglio, P., Trusolino, L., Di Nicolantonio, F., Giordano, S., & Siena, S.
- Affiliations
- Janssen (Belgium) (BE)
- Authors' Affiliations: 1Department of Oncology, University of Torino; 2IRCC Institute for Cancer Research and Treatment at Candiolo, Candiolo, Torino; 3FIRC Institute of Molecular Oncology (IFOM); 4Division of Pathology and 5Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano, Italy;6Janssen Research and Development, Beerse, Belgium; and 7Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland
- Corresponding author
- Bardelli, Alberto
- Giordano, Silvia
- ORCID
- Bardelli, Alberto
- Corso, Simona
- Bertotti, Andrea
- Valtorta, Emanuele
- Siravegna, Giulia
- Scala, Elisa
- Cassingena, Andrea
- Zecchin, Davide
- Migliardi, Giorgia
- Galimi, Francesco
- Lauricella, Calogero
- Zanon, Carlo
- Veronese, Silvio
- Corti, Giorgio
- Amatu, Alessio
- Diaz, Luis A.
- Sausen, Mark
- Velculescu, Victor E.
- Comoglio, Paolo
- Trusolino, Livio
- Giordano, Silvia
- Siena, Salvatore
- Venue
- Cancer Discovery
- Published
- 2013-06-01
- Volume
- 3
- Issue
- 6
- Pages
- 658-673
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4078408
- OpenAlex
- W2007513598
- Cited by
- 657
- References
- 54
- Citations by year
- 2026: 17 · 2025: 32 · 2024: 38 · 2023: 38 · 2022: 37 · 2021: 41 · 2020: 41 · 2019: 57 · 2018: 55 · 2017: 61 · 2016: 77 · 2015: 73 · 2014: 68 · 2013: 22
- FWCI
- 42.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Swim Across America
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- anti-EGFR therapy resistance, KRAS mutation, circulating tumor DNA, MET inhibitors, colorectal cancer, patient-derived xenografts, acquired drug resistance
- MeSH terms
- Cetuximab, Panitumumab, Proto-Oncogene Mas, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Random Allocation, Genes, ras, Colorectal Neoplasms, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0558
- The paper
- Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., Apicella, M., Migliardi, G., Galimi, F., Lauricella, C., Zanon, C., Perera, T., Veronese, S., Corti, G., Amatu, A., . . . Siena, S. (2013). Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.